Marker Therapeutics Inc (NASDAQ: MRKR) on Tuesday, plunged -20.63% from the previous trading day, before settling in for the closing price of $1.26. Within the past 52 weeks, MRKR’s price has moved between $0.95 and $5.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 23.96%. The company achieved an average annual earnings per share of -26.18%. With a float of $9.20 million, this company’s outstanding shares have now reached $11.30 million.
Marker Therapeutics Inc (MRKR) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Marker Therapeutics Inc is 28.91%, while institutional ownership is 9.76%. The most recent insider transaction that took place on Dec 23 ’24, was worth 35,472. In this transaction Director of this company bought 11,085 shares at a rate of $3.20, taking the stock ownership to the 325,370 shares. Before that another transaction happened on Dec 23 ’24, when Company’s 10% Owner bought 554,250 for $3.20, making the entire transaction worth $1,773,600. This insider now owns 1,625,678 shares in total.
Marker Therapeutics Inc (MRKR) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.26 earnings per share (EPS) for the period topping the consensus outlook (set at -0.39) by 0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -26.18% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.97% during the next five years compared to 23.96% growth over the previous five years of trading.
Marker Therapeutics Inc (NASDAQ: MRKR) Trading Performance Indicators
Marker Therapeutics Inc (MRKR) is currently performing well based on its current performance indicators. A quick ratio of 3.45 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.37, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -1.73 in one year’s time.
Technical Analysis of Marker Therapeutics Inc (MRKR)
Looking closely at Marker Therapeutics Inc (NASDAQ: MRKR), its last 5-days average volume was 9.15 million, which is a jump from its year-to-date volume of 0.81 million. As of the previous 9 days, the stock’s Stochastic %D was 54.34%.
During the past 100 days, Marker Therapeutics Inc’s (MRKR) raw stochastic average was set at 1.60%, which indicates a significant decrease from 5.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1099 in the past 14 days, which was lower than the 0.1454 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4358, while its 200-day Moving Average is $1.9186. However, in the short run, Marker Therapeutics Inc’s stock first resistance to watch stands at $1.2750. Second resistance stands at $1.5500. The third major resistance level sits at $1.7000. If the price goes on to break the first support level at $0.8500, it is likely to go to the next support level at $0.7000. Now, if the price goes above the second support level, the third support stands at $0.4250.
Marker Therapeutics Inc (NASDAQ: MRKR) Key Stats
Market capitalization of the company is 12.94 million based on 12,939K outstanding shares. Right now, sales total 6,590 K and income totals -10,730 K. The company made 860 K in profit during its latest quarter, and -4,020 K in sales during its previous quarter.
